Breyer, Johannes and Otto, Wolfgang and Wirtz, Ralph M. and Wullich, Bernd and Keck, Bastian and Erben, Philipp and Kriegmair, Maximilian C. and Stoehr, Robert and Eckstein, Markus and Laible, Mark and Schlombs, Kornelia and Eidt, Sebastian and Denzinger, Stefan and Burger, Maximilian and Hartmann, Arndt (2017) ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. UROLOGIA INTERNATIONALIS, 98 (3). pp. 282-289. ISSN 0042-1138, 1423-0399
Full text not available from this repository. (Request a copy)Abstract
Background/Aims/Objectives: It is difficult to identify patients with a non-muscle-invasive bladder cancer (NMIBC) at stage pT1 with concomitant carcinoma in situ (Cis) who will benefit from an early cystectomy. Methods: We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues of patients with NMIBC. Messenger ribonucleic acid (mRNA) expression of progesterone receptor (PGR), estrogen receptor (ESR1), ERBB2, and marker of proliferation Ki-67 (MKI67) was measured by single-step reverse transcription quantitative real-time polymerase chain reaction using RNA-specific TaqMan assays. Relative gene expression was determined by the normalization of 2 reference genes (CALM2, B2M) using the 40 Delta Delta CT method and relative gene expression was correlated to the histopathological stage and oncological outcome. Results: Of 302 patients with pT1 NMIBC in the initial transurethral resection of the bladder, 65 had a concomitant Cis. Elevated ERBB2 expression (> 40.1) significantly correlated with progress in patients with and without concomitant Cis (p = 0.020 and p = 0.049, respectively). For the subgroup of pT1 with concomitant Cis, elevated ERBB2 expression significantly discriminated between a high-risk group of 55% progression-free survival (PFS) and a low-risk group of 90% PFS after a 5-year follow-up (p = 0.020). Coxregression analysis revealed ERBB2 expression as the only independent prognostic factor for PFS (p = 0.0037). Conclusions: High mRNA expression of ERBB2 can identify patients with pT1 NMIBC with concomitant Cis, who have a high risk of progression and might benefit from an early cystectomy. (C) 2016 S. Karger AG, Basel
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BACILLUS-CALMETTE-GUERIN; UROTHELIAL CARCINOMA; PROGNOSTIC-FACTORS; KI67 EXPRESSION; GRADE; HER2; P53; PROGRESSION; SURVIVAL; SUBTYPES; Bladder cancer; Non-muscle-invasive bladder cancer; ERBB2; Carcinoma in situ; Progression; Prognostic factors |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 12:57 |
| Last Modified: | 19 Feb 2019 15:02 |
| URI: | https://pred.uni-regensburg.de/id/eprint/39 |
Actions (login required)
 |
View Item |
